New developments from Centocor described

This trend article is an immediate alert from NewsRx to identify the most recent news developments at Centocor.

Report 1: Findings presented today at Digestive Disease Week(R) 2007 (DDW), from long-term extensions of the ACT trials (Active Ulcerative Colitis 1 & 2) show that subjects with moderately to severely active ulcerative colitis who had responded to REMICADE(R) (infliximab) in the blinded phase of the trials maintained improvement in their clinical symptoms for up to two years.

The ACT extension trials were conducted in both the United States and Europe, under co-principle...

Want to see the full article?

• Purchase this article for only $3.00